Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06144151 · ClinicalTrials.gov registry record
A Pilot Study for Pupillary Assessment to Predict CAR-T Related Neurotoxicity
A clinical trial of Neurotoxicity, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT06144151: Recruiting study of Neurotoxicity, sponsored by M.D. Anderson Cancer Center.
NCT06144151 is a study of Neurotoxicity that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 100 participants, below the 208-participant average among 10 other Neurotoxicity trials with a reported enrollment target (52% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06144151, a study of Neurotoxicity, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
To learn about the relationship between changes in pupil size and reactivity and the start of neurological side effects in patients after receiving CAR-T cell therapy.
Conditions Studied
Interventions
- DEVICE NeurOptics® NPi®-300 Pupillometer
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2024-02-08 |
| Est. Completion | 2027-04-01 |
What NCT06144151 shows while recruiting
NCT06144151 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 208-participant average among 10 other Neurotoxicity trials with a reported enrollment target (52% lower).
The record links to 1 condition, with Neurotoxicity appearing as the primary indexed condition, and to 1 intervention - of which NeurOptics® NPi®-300 Pupillometer is the first listed.
NCT06144151 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06144151 about?
NCT06144151 is a clinical study titled "A Pilot Study for Pupillary Assessment to Predict CAR-T Related Neurotoxicity". To learn about the relationship between changes in pupil size and reactivity and the start of neurological side effects in patients after receiving CAR-T cell therapy.
What is the current status of trial NCT06144151?
This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2024-02-08. Estimated completion is 2027-04-01.
What conditions does trial NCT06144151 study?
This clinical trial studies the following conditions: Neurotoxicity.
What interventions are being tested in trial NCT06144151?
The interventions under investigation include: NeurOptics® NPi®-300 Pupillometer (DEVICE).
Who is sponsoring clinical trial NCT06144151?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06144151 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neurotoxicity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06144151's enrollment target sits among peer trials
100 7th of 10 higher than 4 of 10 other Neurotoxicity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neurotoxicity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Compare the Long-term Outcomes After Two Different Anaesthetics
ACTIVE NOT RECRUITING · Phase 3
-
Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity Caused By Oxaliplatin in Patients Receiving Combination Chemotherapy for Stage II, Stage III, or Stage IV Colorectal Cancer That Has Been Completely Removed By Surgery
COMPLETED · Phase 3
-
Natural History of Brain Function, Quality of Life, and Seizure Control in Patients With Brain Tumor Who Have Undergone Surgery
COMPLETED
-
Duloxetine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
COMPLETED · Phase 3
-
Effects of Chemotherapy on the Brain in Women With Newly Diagnosed Early-Stage Breast Cancer
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI